Editor's Choice
Lilly’s Ulcerative Colitis Therapy Mirikizumab Finally Snags FDA Approval31 Oct 2023
On Thursday, the FDA approved Eli Lilly’s mirikizumab (Omvoh) for adults with moderate to severe ulcerative colitis, marking its first... Continue Reading
|
Chan Zuckerberg Initiative Launches Biohub in New York for Early Disease Prevention, Detection, and Treatment21 Oct 2023
The Chan Zuckerberg Initiative (CZI) has unveiled a new biomedical research hub, CZ Biohub NY, in New York City. This... Continue Reading
|
Flagship’s Laronde, Senda Form Company Focused on New Class of Medicines21 Oct 2023
Flagship Pioneering’s life science ventures, Laronde and Senda Biosciences, have merged to create Sail Biomedicines. This innovative company will leverage... Continue Reading
|
6 Digital Health Executives Share Key Takeaways from HLTH2321 Oct 2023
The HLTH conference offered an inspiring atmosphere of collaboration and innovation in the face of healthcare challenges. Participants discussed merging... Continue Reading
|
Inovalon & AWS to Develop AI/ML Solutions for Healthcare21 Oct 2023
Amazon Web Services (AWS) and Inovalon have joined forces to develop AI and ML-driven solutions for healthcare organizations, aiming to... Continue Reading
|
Ozempic: From Diabetes Management to Potential Weight Loss Miracle21 Oct 2023
Ozempic, initially designed to treat Type 2 diabetes, has gained immense popularity, particularly on social media platforms like TikTok. Influencers... Continue Reading
|
Early October Sees Torrid Pace of Biotech M&A—Will It Continue?17 Oct 2023
In recent biotech M&A news, Bristol Myers Squibb acquired Mirati Therapeutics for $4.8 billion, signaling a resurgence in deal activity... Continue Reading
|
GE HealthCare Inks $44M Contract with BARDA to Develop AI-Driven Ultrasound Tech17 Oct 2023
GE Healthcare has secured a $44 million contract with the Biomedical Advanced Research and Development Authority (BARDA) to create and... Continue Reading
|
Financial Distress Driving Q3 Healthcare Deals17 Oct 2023
In Q3 2023, over one-third of hospital and health system transactions were driven by financial distress, according to Kaufman Hall’s... Continue Reading
|
EU Orders Illumina to Divest Grail After Years of Regulatory Challenges17 Oct 2023
The European Commission is set to compel Illumina to divest Grail, a cancer testing company it acquired for $8 billion... Continue Reading
|